TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18591457

Group type: EXPERIMENTAL
Intervention: Valsartan (low-, medium-, or high-dose)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 11295408

Group type: EXPERIMENTAL
Intervention: 3 g fosfomycin trometamol (single-dose)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 400 mg ceftibuten (3-day course)
Number of subjects: 100
Study: 9136253

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 37

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 37
Study: 7970503

Group type: EXPERIMENTAL
Intervention: Cyclical, sequential combination of tamoxifen and megestrol acetate (group B)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Tamoxifen alone (group A)
Number of subjects: 261
Study: 3310318

Group type: EXPERIMENTAL
Intervention: Metformin (1.7 g/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 28273752

Group type: EXPERIMENTAL
Intervention: Codetalk, a simulation-based workshop
Number of subjects: 472

Group type: COMPARATOR
Intervention: Usual education
Number of subjects: 472
Study: 28787507

Group type: EXPERIMENTAL
Intervention: Levosimendan (0.1 µg/kg/min for 24 hours)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 336
Study: 26978493

Group type: EXPERIMENTAL
Intervention: D‐, L‐hopantenic acid (pantogam active) at a daily dose of 600 to 1200 mg for 28 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard cardiotropic hypotensive treatment (Control)
Number of subjects: 80
Study: 24139424

Group type: EXPERIMENTAL
Intervention: Delayed-release dimethyl fumarate (DR-DMF)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Delayed-release dimethyl fumarate (DR-DMF) with aspirin pretreatment
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 20878292

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss treatment
Number of subjects: 203

Group type: COMPARATOR
Intervention: Behavioral weight loss combined with cognitive‐behavioral depression management
Number of subjects: 203
Study: 18444133

Group type: EXPERIMENTAL
Intervention: Intervention participants (dietary energy density reduction)
Number of subjects: 2718

Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 2718

Group type: EXPERIMENTAL
Intervention: Intervention participants
Number of subjects: 2718
Study: 17021318

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 mg
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 716

Group type: COMPARATOR
Intervention: Sham injections
Number of subjects: 716
Study: 14618246

Group type: EXPERIMENTAL
Intervention: HYPER‐HES (150 ml/m2 hypertonic NaCl (7.2%) 10% HES 200/0.5)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: HYPER‐DEX (150 ml/m2 hypertonic NaCl (7.2%) 10% dextran 60)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: HES (250 ml/m2 10% HES 200/0.5 plus 400 ml/m2 NaCl 0.9%)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: DEX (250 ml/m2 10% dextran 40 plus 300 ml/m2 NaCl 0.9%)
Number of subjects: 43

Group type: COMPARATOR
Intervention: NACL (750 ml/m2 NaCl 0.9%)
Number of subjects: 43
Study: 10763156

Group type: EXPERIMENTAL
Intervention: Exercise Group (EG) - 16 weeks of aerobic training at 75% to 85% of maximum capacity, three 1-hour bouts/week.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control Group (CG) - No exercise.
Number of subjects: 18
Study: 8694323

Group type: EXPERIMENTAL
Intervention: 10 mL bupivacaine 0.5% (Group 1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 10 mL saline (Group 2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No epidural top-up (Group 3)
Number of subjects: 30
Study: 1562255

Group type: EXPERIMENTAL
Intervention: Dorzolamide 0.7%
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Dorzolamide 1.4%
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Dorzolamide 2%
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 31770235

Group type: EXPERIMENTAL
Intervention: Vitamin D treatment
Number of subjects: 828

Group type: COMPARATOR
Intervention: No vitamin D treatment
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency (not receiving treatment)
Number of subjects: 828
Study: 30304108

Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Alendronate + Curcumin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 27603001

Group type: EXPERIMENTAL
Intervention: Prolotherapy (intra- and extra-articular hypertonic dextrose injection)
Number of subjects: 22
Study: 25132212

Group type: EXPERIMENTAL
Intervention: Alogliptin 12.5 mg once daily (n = 880)
Number of subjects: 2639

Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg once daily (n = 885)
Number of subjects: 2639

Group type: COMPARATOR
Intervention: Glipizide 5 mg once daily, titrated to a maximum of 20 mg (n = 874)
Number of subjects: 2639
Study: 22243959

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (mean 40.6 mg, SD 25 mg)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Intravenous morphine alone (mean 14.4 mg, SD 9.4 mg)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Comparison of ketamine and morphine
Number of subjects: 135
Study: 19858761

Group type: EXPERIMENTAL
Intervention: Combined treatment (COMB) with risperidone and parent training (PT)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Medication alone (MED)
Number of subjects: 124
Study: 18281620

Group type: EXPERIMENTAL
Intervention: Multilevel botulinum toxin A injections
Number of subjects: 46
Study: 16168278

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 100 mg/day administered before bedtime
Number of subjects: 328

Group type: COMPARATOR
Intervention: Aspirin (ASA) 100 mg/day administered on awakening
Number of subjects: 328

Group type: COMPARATOR
Intervention: Nonpharmacological hygienic-dietary recommendations
Number of subjects: 328
Study: 12514662

Group type: EXPERIMENTAL
Intervention: TIMI 9B trial
Number of subjects: 3002

Group type: COMPARATOR
Intervention: Not enrolled in TIMI 9B (Control)
Number of subjects: 3002

Group type: COMPARATOR
Intervention: Ineligible patients not treated with reperfusion therapy (Control)
Number of subjects: 3002
Study: 10536645

Group type: EXPERIMENTAL
Intervention: Caregivers of Alzheimer's patients
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Older women
Number of subjects: 70

Group type: COMPARATOR
Intervention: Movers (older women assessed one month before relocation)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: All women
Number of subjects: 70
Study: 8683232

Group type: EXPERIMENTAL
Intervention: Oral etoposide phosphate (EP) at 125 mg/m2/d for 5 days
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Oral etoposide phosphate (EP) at 150 mg/m2/d for 5 days
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Intravenous etoposide (E) at 80 mg/m2 for 1 hour
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Oral etoposide phosphate (EP)
Number of subjects: 29
Study: 2054272

Group type: EXPERIMENTAL
Intervention: Propranolol (repeated administration)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Verapamil and Propranolol (co-administered as single doses)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Propranolol (repeated doses)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Verapamil and Propranolol (single and repeated oral doses in combination)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Verapamil and Propranolol (single doses in combination)
Number of subjects: 6
Study: 6474840

Group type: EXPERIMENTAL
Intervention: 2 sec period of inspection of the grating or its fundamental preceding the test presentation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Test presentation of gratings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low contrast and high frequency test presentations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Real or simulated afterimages present during triangular-wave gratings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative afterimage effects eliminated
Number of subjects: 0
Study: 31390454

Group type: EXPERIMENTAL
Intervention: Rapid Maxillary Expansion (RME)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Slow Maxillary Expansion (SME)
Number of subjects: 32
Study: 30716803

Group type: EXPERIMENTAL
Intervention: Post-auricular subperiosteal injection of methylprednisolone combined with ginkgo biloba injection and mouse nerve growth factor
Number of subjects: 84

Group type: COMPARATOR
Intervention: Ginkgo biloba injection and mouse nerve growth factor
Number of subjects: 84
Study: 26486632

Group type: EXPERIMENTAL
Intervention: Positive Thoughts and Actions (PTA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Individual Support Program (ISP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Parent-reported internalizing symptoms and health behavior
Number of subjects: 120
Study: 25245975

Group type: EXPERIMENTAL
Intervention: CGI
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: IGT
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: IFG
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: elevated HbA1c
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: 30-min postload glucose ≥ 165 mg/dL and 30-min C-peptide < 5 ng/mL
Number of subjects: 406
Study: 22092097

Group type: EXPERIMENTAL
Intervention: Realistic simulation (n = 31)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Traditional test (n = 33)
Number of subjects: 64
Study: 19464177

Group type: EXPERIMENTAL
Intervention: Fulvestrant (250 mg/month)
Number of subjects: 14
Study: 17513663

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia and analgesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anesthesia followed by patient-controlled analgesia (control group)
Number of subjects: 60
Study: 15204446

Group type: EXPERIMENTAL
Intervention: Teaching-learning programme using an interaction analysis system and video observation
Number of subjects: 36
Study: 11590993

Group type: EXPERIMENTAL
Intervention: Wine ethanol intake
Number of subjects: 437
Study: 9852885

Group type: EXPERIMENTAL
Intervention: CABG plus ICD implantation
Number of subjects: 900
Study: 7537664

Group type: COMPARATOR
Intervention: Casodex 50 mg/day
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Casodex 150 mg/day
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Casodex 50 mg/day for prostate cancer
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Casodex 50 mg/day for benign prostatic hyperplasia (BPH)
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Casodex (various doses)
Number of subjects: 3000
Study: 2686666

Group type: EXPERIMENTAL
Intervention: Home exercise program
Number of subjects: 30

Group type: COMPARATOR
Intervention: Supervised outpatient physical therapy
Number of subjects: 30
Study: 4392984

Group type: EXPERIMENTAL
Intervention: Practolol
Number of subjects: 24
Study: 31820568

Group type: EXPERIMENTAL
Intervention: Optimized criteria combining triple hematologic parameters for NRBC
Number of subjects: 2491

Group type: EXPERIMENTAL
Intervention: Optimized criteria combining triple hematologic parameters for AL
Number of subjects: 2491

Group type: COMPARATOR
Intervention: Default setting for NRBC
Number of subjects: 2491

Group type: COMPARATOR
Intervention: Default setting for AL
Number of subjects: 2491
Study: 30314725

Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic cholecystectomy
Number of subjects: 120

Group type: COMPARATOR
Intervention: 4-port laparoscopic cholecystectomy
Number of subjects: 120
Study: 28463899

Group type: EXPERIMENTAL
Intervention: Standing posture
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sitting posture
Number of subjects: 18
Study: 25792076

Group type: EXPERIMENTAL
Intervention: M1-TMS
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: SMA-TMS
Number of subjects: 26

Group type: COMPARATOR
Intervention: Cerebellar TMS
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: M1-TMS in PD
Number of subjects: 26
Study: 24187226

Group type: EXPERIMENTAL
Intervention: iPAM MkII system for assistive upper-limb exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 21548943

Group type: EXPERIMENTAL
Intervention: Interventions focused on increasing physician familiarity with and motivation to follow guidelines.
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Improving self-efficacy in performing guideline concordant care.
Number of subjects: 156
Study: 18070967

Group type: EXPERIMENTAL
Intervention: APL 600 mg BID
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: APL 800 mg BID
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: APL 200 mg BID
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: APL 400 mg BID
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: APL 800 mg once a day
Number of subjects: 342

Group type: COMPARATOR
Intervention: ZDV-3TC
Number of subjects: 342

Group type: COMPARATOR
Intervention: EFV
Number of subjects: 342

Group type: COMPARATOR
Intervention: LPV-RTV
Number of subjects: 342
Study: 17126779

Group type: EXPERIMENTAL
Intervention: 5% albumin (5 mL/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lactated Ringer's solution (25 mL/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both fluids
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 5% albumin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 20
Study: 14566178

Group type: EXPERIMENTAL
Intervention: Low iodine concentration (300 mg/mL) at slow flow rate (2.5 mL/s)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low contrast concentration (300 mg/mL) at high flow rate (3.5 mL/s)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High contrast concentration (400 mg/mL) at high flow rate (3.5 mL/s)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Approximately 1 g iodine/s
Number of subjects: 60
Study: 10926127

Group type: EXPERIMENTAL
Intervention: Vignette describing AIDS as lethal
Number of subjects: 136

Group type: COMPARATOR
Intervention: Vignette describing AIDS as chronic
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Both vignettes (lethal vs chronic)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Psychosocial variables
Number of subjects: 136
Study: 8900980

Group type: EXPERIMENTAL
Intervention: Hypovolemic condition (induced by 30 mg furosemide)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normovolemic condition
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hypovolemic condition
Number of subjects: 8
Study: 2049253

Group type: EXPERIMENTAL
Intervention: PGE1 (Prostaglandin E1) infused at doses ranging from 0.01 to 1.3 micrograms kg‐1 min‐1
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control saline solution (isotonic)
Number of subjects: 10
Study: 6404193

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Disodium Cromoglycate (DSCG)
Number of subjects: 14
Study: 30412032

Group type: COMPARATOR
Intervention: HYP-PLA (placebo drink in hypoxia)
Number of subjects: 12

Group type: COMPARATOR
Intervention: NORM-PLA (placebo drink in normoxia)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: HYP-CHO (carbohydrate solution in hypoxia)
Number of subjects: 12
Study: 30174193

Group type: EXPERIMENTAL
Intervention: Duodenal-jejunal bypass surgery with minimal gastric resection
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 21
Study: 28095936

Group type: EXPERIMENTAL
Intervention: Cardioprotective diet
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional UK diet
Number of subjects: 40
Study: 26813138

Group type: EXPERIMENTAL
Intervention: Ligation of the Intersphincteric Fistula Tract Plus Bioprosthetic Anal Fistula Plug (LIFT‐plug)
Number of subjects: 239

Group type: COMPARATOR
Intervention: LIFT (control)
Number of subjects: 239
Study: 24643485

Group type: EXPERIMENTAL
Intervention: Basic intervention program (physical activity and nutrition)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Plus intervention program (physical activity and nutrition)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 27
Study: 21242192

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 10837

Group type: COMPARATOR
Intervention: No vitamin E
Number of subjects: 10837
Study: 18495372

Group type: EXPERIMENTAL
Intervention: High-tech external beam therapy (EBT)
Number of subjects: 9

Group type: COMPARATOR
Intervention: High-tech brachytherapy (BT)
Number of subjects: 9
Study: 16541932

Group type: EXPERIMENTAL
Intervention: Intensive rehabilitation (six or more face-to-face contacts)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Non-intensive rehabilitation (three or less face-to-face contacts)
Number of subjects: 160
Study: 12656706

Group type: EXPERIMENTAL
Intervention: Web-based self-help program with e-mail support + weekly individual telephone calls
Number of subjects: 44

Group type: COMPARATOR
Intervention: Web-based self-help program with e-mail support (Internet-only group)
Number of subjects: 44
Study: 11023140

Group type: EXPERIMENTAL
Intervention: Intensive treatment (goal HbA(1c) 7.1%)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Standard treatment (goal HbA(1c) 9.1%)
Number of subjects: 153
Study: 9083166

Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone (124 +/- 22 mg per day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Controlled-release hydromorphone (30 +/- 6 mg per day)
Number of subjects: 44
Study: 7689826

Group type: EXPERIMENTAL
Intervention: Laser photocoagulation of extrafoveal CNV
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Bilateral neovascular maculopathy
Number of subjects: 228

Group type: COMPARATOR
Intervention: Unilateral neovascular maculopathy
Number of subjects: 228
Study: 3789915

Group type: EXPERIMENTAL
Intervention: High-dose doxorubicin therapy
Number of subjects: 118

Group type: COMPARATOR
Intervention: Low-dose doxorubicin therapy
Number of subjects: 118
Study: 30075780

Group type: EXPERIMENTAL
Intervention: Interactive power toothbrush (IPT) - Oral-B® ProfessionalCare 6000 with Bluetooth
Number of subjects: 60

Group type: COMPARATOR
Intervention: Manual toothbrush (MT) - Oral-B® Indicator soft manual toothbrush
Number of subjects: 60
Study: 27385662

Group type: EXPERIMENTAL
Intervention: Uncontrolled BP (HT2 group)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Controlled BP (HT1 group)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 276
Study: 24780850

Group type: EXPERIMENTAL
Intervention: Intradiskal methylene blue injection
Number of subjects: 16
Study: 23333134

Group type: EXPERIMENTAL
Intervention: 4-week slackline training
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no slackline training)
Number of subjects: 24
Study: 20192136

Group type: EXPERIMENTAL
Intervention: Local infiltration anesthesia
Number of subjects: 85

Group type: COMPARATOR
Intervention: Epidural anesthesia
Number of subjects: 85
Study: 18334911

Group type: EXPERIMENTAL
Intervention: Iloperidone 12 mg/d
Number of subjects: 1943

Group type: EXPERIMENTAL
Intervention: Iloperidone 4-8 mg/d
Number of subjects: 1943

Group type: EXPERIMENTAL
Intervention: Iloperidone 10-16 mg/d
Number of subjects: 1943

Group type: EXPERIMENTAL
Intervention: Iloperidone 20-24 mg/d
Number of subjects: 1943

Group type: COMPARATOR
Intervention: Haloperidol 15 mg/d
Number of subjects: 1943

Group type: COMPARATOR
Intervention: Risperidone 4-8 mg/d
Number of subjects: 1943

Group type: EXPERIMENTAL
Intervention: Iloperidone
Number of subjects: 1943
Study: 16337518

Group type: EXPERIMENTAL
Intervention: Pyridostigmine bromide (45 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 14602790

Group type: EXPERIMENTAL
Intervention: Adrenaline (0.04, 0.06, and 0.08 microg.kg(‐1).min(‐1))
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 16
Study: 10759336

Group type: EXPERIMENTAL
Intervention: St John's wort extract (hypericum Ze 117)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 240
Study: 8723448

Group type: EXPERIMENTAL
Intervention: Penicillin G (3 g every 6 hours)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg every 24 hours)
Number of subjects: 46
Study: 1328358

Group type: EXPERIMENTAL
Intervention: Hormonal therapy (5-10 mg norethynodrel with mestranol 0.075-0.15 mg or conjugated estrogens 0.625 mg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no hormonal therapy)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Hormonal therapy
Number of subjects: 64
Study: 3526804

Group type: EXPERIMENTAL
Intervention: Tinidazole 1,600 mg i.v. preoperatively
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 30029756

Group type: EXPERIMENTAL
Intervention: Partnership intervention (experimental group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine home visits (control group)
Number of subjects: 0
Study: 26983925

Group type: EXPERIMENTAL
Intervention: Lidocaine cream applied from wrist to shoulder
Number of subjects: 31

Group type: COMPARATOR
Intervention: Neutral cream (placebo) applied to the same skin area
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Lidocaine cream
Number of subjects: 31

Group type: COMPARATOR
Intervention: Neutral cream (placebo)
Number of subjects: 31
Study: 24106340

Group type: EXPERIMENTAL
Intervention: Active doxycycline (100 mg BID for 7 days)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo doxycycline
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Active azithromycin
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo azithromycin
Number of subjects: 184
Study: 21880289

Group type: EXPERIMENTAL
Intervention: High on-treatment platelet reactivity (HOPR) defined as OPR ≥235 P2Y12 reactivity units
Number of subjects: 809

Group type: COMPARATOR
Intervention: Normal on-treatment platelet reactivity (non-HOPR)
Number of subjects: 809
Study: 15937529

Group type: EXPERIMENTAL
Intervention: Mobile phone text messaging intervention providing smoking cessation advice, support, and distraction (5 messages per day for 1 month, then 3 per week until 26-week follow-up)
Number of subjects: 1705

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 1705

Group type: EXPERIMENTAL
Intervention: Mobile phone text messaging intervention
Number of subjects: 1705